Graves' disease hair loss is one of the most distressing symptoms experienced by people living with this autoimmune thyroid condition. Graves' disease causes the immune system to overstimulate the thyroid gland, leading to excess thyroid hormone production that disrupts the hair growth cycle and results in diffuse shedding. Understanding why this happens, how it is diagnosed, and what treatments are available on the NHS can help patients feel more informed and reassured. Crucially, in most cases, hair loss associated with Graves' disease is reversible once thyroid hormone levels are brought back under control.

Why Graves' Disease Causes Hair Loss

Graves' disease causes diffuse telogen effluvium by driving excess thyroid hormone production, which pushes hair follicles prematurely into the shedding phase; antithyroid medications carbimazole and PTU may also contribute to hair thinning.

Graves' disease is an autoimmune condition in which the immune system mistakenly produces antibodies — known as stimulating TSH receptor antibodies (TRAb), sometimes referred to in older literature as thyroid-stimulating immunoglobulins (TSIs) — that overstimulate the thyroid gland. This leads to hyperthyroidism, a state of excess thyroid hormone production that affects virtually every system in the body, including the skin and hair follicles. Diffuse hair thinning is a recognised symptom of hyperthyroidism and is listed in NHS resources on overactive thyroid.

Hair loss, medically termed alopecia, is a well-recognised feature of untreated or poorly controlled Graves' disease. The most common pattern is diffuse telogen effluvium, where a large proportion of hair follicles are simultaneously pushed into the resting (telogen) phase of the hair cycle, leading to widespread shedding rather than patchy loss. Patients often notice increased hair on their pillow, in the shower drain, or when brushing.

Not sure if this is normal? Chat with one of our pharmacists →

It is also important to note that Graves' disease is associated with other autoimmune conditions, including alopecia areata — a separate condition causing patchy hair loss — due to shared immune dysregulation pathways. If hair loss is patchy rather than diffuse, this distinction should be explored with a clinician.

Some medications used to treat Graves' disease, particularly carbimazole and propylthiouracil (PTU), list alopecia or hair thinning as uncommon adverse effects in their Summaries of Product Characteristics (SmPCs); causality may be multifactorial and should be discussed with a prescriber. Understanding the underlying cause of hair loss is therefore an important first step before pursuing any treatment.

If you suspect a medicine is causing a side effect, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

How Thyroid Hormones Affect Hair Growth

Elevated T3 and T4 in Graves' disease shorten the anagen (growth) phase and accelerate follicle entry into telogen, causing widespread shedding that typically becomes visible two to four months after hormonal disruption begins.

The hair follicle is one of the most metabolically active structures in the human body, and it is exquisitely sensitive to hormonal fluctuations. Thyroid hormones — primarily triiodothyronine (T3) and thyroxine (T4) — play a direct role in regulating the hair growth cycle, which consists of three main phases:

• Anagen – the active growth phase, lasting two to seven years

• Catagen – a short transitional phase

• Telogen – the resting and shedding phase, lasting approximately three months

In Graves' disease, chronically elevated levels of T3 and T4 disrupt the normal duration of these phases. Excess thyroid hormone accelerates cellular metabolism throughout the body, which paradoxically shortens the anagen phase and prematurely shifts follicles into telogen. The result is a higher-than-normal proportion of hairs shedding simultaneously — a process that may not become visibly apparent until two to four months after the hormonal disruption begins, due to the natural lag in the hair cycle.

Beyond the hair cycle itself, hyperthyroidism can also impair the structural integrity of the hair shaft, leading to hair that appears fine, brittle, or lacking lustre.

Nutritional deficiencies may compound hair loss in some patients. Iron deficiency (low ferritin) is the most clinically relevant and commonly assessed; a full blood count and serum ferritin are the appropriate first-line tests. Vitamin D or zinc levels may be checked if there is a specific clinical reason to suspect deficiency, but routine testing for all micronutrients is not standard UK practice.

Patients should be aware that high-dose biotin (vitamin B7) supplements can interfere with immunoassay-based laboratory tests, including thyroid function tests, potentially producing falsely abnormal results. The MHRA has issued safety advice on this. If you are taking biotin supplements, inform your GP or laboratory before blood tests are taken, as it may be necessary to pause supplementation beforehand in line with local laboratory guidance.

Diagnosing Hair Loss Related to Graves' Disease

Diagnosis involves thyroid function tests including TSH, free T4, and TRAb antibodies, alongside FBC and serum ferritin to exclude iron deficiency; NICE NG145 recommends endocrinology referral for confirmed hyperthyroidism.

Diagnosing hair loss in the context of Graves' disease requires a structured clinical approach to confirm the thyroid aetiology and exclude other contributing causes. A GP will typically begin with a thorough history, asking about the pattern, onset, and duration of hair loss, alongside any other symptoms of hyperthyroidism such as palpitations, weight loss, heat intolerance, tremor, or anxiety.

Blood tests form the cornerstone of investigation and will usually include:

• TSH (thyroid-stimulating hormone) — typically suppressed in Graves' disease

• Free T4 (and free T3 if indicated) — usually elevated

• TRAb (stimulating TSH receptor antibodies) — a specific marker for Graves' disease

• Full blood count (FBC) and serum ferritin — to identify iron deficiency, the most common nutritional contributor to hair loss; transferrin saturation may be added if clinically indicated

• Vitamin D or zinc levels may be checked selectively if there is clinical suspicion of deficiency, but are not required routinely

A dermatological assessment may also be warranted, particularly if the hair loss pattern is patchy, to differentiate telogen effluvium from alopecia areata or other dermatological conditions. In some cases, a trichoscopy (dermoscopy of the scalp) or scalp biopsy may be performed by a specialist.

NICE guideline NG145 Thyroid disease: assessment and management (2019, updated) recommends that patients with confirmed hyperthyroidism are referred to an endocrinologist for specialist management.

Red flags requiring prompt or urgent assessment:

• Visual disturbance, eye pain, or significant eye protrusion may indicate thyroid eye disease and warrant same-day or urgent ophthalmology review

• Palpitations with an irregular pulse may suggest atrial fibrillation and require prompt cardiac assessment

• Severe or rapidly worsening hyperthyroid symptoms should prompt urgent referral

Hair loss, whilst distressing, is generally considered a secondary concern that resolves as thyroid function is brought under control. However, if hair loss persists despite euthyroid status (normal thyroid levels), further dermatological investigation is appropriate. Patients should not self-diagnose or self-treat without professional assessment.

Treatment Options Available on the NHS

The NHS offers three treatments for Graves' disease — carbimazole (first-line), radioactive iodine, and thyroidectomy — all aimed at restoring normal thyroid levels, which is the primary means of resolving associated hair loss.

The primary treatment goal in Graves' disease is to restore normal thyroid hormone levels, which in turn addresses the underlying cause of hair loss. The NHS offers three main treatment modalities for Graves' disease, each with different implications for long-term management.

1. Antithyroid medications Carbimazole is the first-line antithyroid drug used in the UK. It works by inhibiting the enzyme thyroid peroxidase, thereby reducing the synthesis of T3 and T4. A standard treatment course typically lasts 12–18 months.

Propylthiouracil (PTU) is an alternative, most commonly used in the first trimester of pregnancy, after which a switch back to carbimazole is usually considered due to the risk of serious PTU-associated hepatotoxicity. Carbimazole is teratogenic and must be used with caution in women of childbearing age; patients should use effective contraception and seek urgent medical review if pregnancy occurs whilst taking it.

Before starting antithyroid drugs, a baseline full blood count (FBC) and liver function tests (LFTs) are recommended. Both carbimazole and PTU carry a small but serious risk of agranulocytosis (a dangerous reduction in white blood cells). Patients must be advised to stop the medication immediately and seek urgent medical attention if they develop a sore throat, fever, or mouth ulcers. Signs of liver injury — including jaundice, dark urine, or persistent abdominal pain — should also prompt immediate cessation of PTU and urgent review.

Beta-blockers (such as propranolol) may be prescribed alongside antithyroid drugs to provide symptomatic relief from palpitations, tremor, and anxiety whilst awaiting euthyroidism, as recommended by NICE NG145.

2. Radioactive iodine (RAI) therapy RAI is a definitive treatment that selectively destroys overactive thyroid tissue. It is administered as a single oral dose and is widely available on the NHS. Most patients subsequently develop hypothyroidism and require lifelong levothyroxine replacement.

RAI is contraindicated in pregnancy and breastfeeding. Women must use effective contraception and avoid becoming pregnant for at least six months after treatment (or as advised by their specialist). Brief radiation precautions — such as limiting close contact with young children and pregnant women for a period after treatment — will be explained by the treating team.

RAI should generally be avoided in patients with active or high-risk thyroid eye disease, as it may worsen this condition. In patients with mild thyroid eye disease who proceed with RAI, steroid prophylaxis may be considered; this decision is made by the specialist team.

3. Thyroidectomy Surgical removal of all or part of the thyroid gland is considered when other treatments are unsuitable or have failed. Like RAI, it often results in hypothyroidism requiring lifelong hormone replacement.

Managing hair loss specifically No additional NHS-funded treatments are routinely offered for hair loss beyond optimising thyroid control. If nutritional deficiencies are identified, supplementation (for example, with iron or vitamin D) may be recommended. If alopecia areata is suspected alongside Graves' disease, or if hair loss persists despite euthyroidism, referral to a dermatologist is appropriate. Patients experiencing significant psychological distress from hair loss may also benefit from support through NHS talking therapies.

When to Expect Hair Regrowth After Treatment

Noticeable hair regrowth typically begins three to six months after achieving euthyroidism, with full density recovery taking up to twelve months; persistent loss beyond six months of normal thyroid levels warrants GP reassessment.

One of the most reassuring aspects of Graves' disease-related hair loss is that it is, in the majority of cases, reversible. Once thyroid hormone levels are stabilised within the normal range — a state known as euthyroidism — the hair follicles can re-enter the anagen (growth) phase and begin to recover. However, patients should be prepared for the fact that regrowth is not immediate.

Typically, noticeable hair regrowth begins three to six months after thyroid function has been adequately controlled. Full recovery of hair density may take six to twelve months or longer, depending on the duration and severity of the hyperthyroid state, the individual's nutritional status, and any concurrent conditions. Hair may initially regrow with a slightly different texture — often finer or curlier — before returning to its previous character.

Patients who begin levothyroxine replacement (following RAI or thyroidectomy) should be aware that temporary hair shedding can occur in the early weeks of treatment; this is a recognised and usually self-limiting effect listed in the levothyroxine patient information leaflet. It is important that levothyroxine dosing is carefully monitored, as over-replacement leading to iatrogenic (treatment-induced) hyperthyroidism can itself perpetuate hair loss.

If hair loss continues despite confirmed euthyroid status for more than six months, patients should return to their GP for reassessment. Persistent hair loss may indicate:

• Concurrent alopecia areata or another autoimmune hair condition

• Ongoing nutritional deficiency (particularly iron deficiency, which is common in women)

• Medication-related hair loss from antithyroid drugs or levothyroxine

• An unrelated dermatological condition

In such cases, GP review and consideration of dermatology referral is appropriate.

Patients are encouraged to maintain regular thyroid function monitoring as advised by their endocrinologist or GP. Emotional support and patient education are equally important — organisations such as the British Thyroid Foundation offer valuable resources for those living with Graves' disease and its associated symptoms.

Frequently Asked Questions